文献速递消化系统肿瘤

CCL5与CCR5基因多态性在转移性结直肠癌表皮生长因子受体信号阻断中的作用:FIRE-3试验分析

Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.
PubMed 文献 · Eur J Cancer · 2018-12-14

基于FIRE-3试验中491例KRAS野生型转移性结直肠癌患者,评估队列244例接受西妥昔单抗联合FOLFIRI,对照队列247例接受贝伐珠单抗联合FOLFIRI,分析CCL5/CCR5单核苷酸多态性与疗效的关系。结果显示,评估队列中CCL5 rs2280789携带G等位基因者总生存较短(HR 1.56,P=0.024),且CCL5与CCR5多态性对结局的影响因原发肿瘤部位而异,对照队列中未观察到显著关联。

要点

  • 评估队列中CCL5 rs2280789携带G等位基因者总生存较A/A型缩短(HR 1.56,P=0.024)。
  • CCR5 rs1799988携带T等位基因者缓解率有低于C/C型的趋势(68% vs 81%,P=0.078)。
  • CCL5/CCR5多态性与结局的关联因原发肿瘤部位而异,对照队列中无显著关联。

核心结论

  • CCL5与CCR5单核苷酸多态性可能预测接受以西妥昔单抗为基础治疗的转移性结直肠癌患者的结局,且取决于肿瘤部位。

研究设计与样本

  • 研究从FIRE-3试验中KRAS野生型转移性结直肠癌患者提取基因组DNA,共491例样本,分两个队列。
  • 评估队列244例接受西妥昔单抗联合FOLFIRI,对照队列247例接受贝伐珠单抗联合FOLFIRI。
  • 采用聚合酶链反应直接测序分析CCL5与CCR5基因的单核苷酸多态性。

主要发现

  • 评估队列中携带CCL5 rs2280789 G等位基因者总生存较A/A型缩短(HR 1.56,P=0.024)。
  • 评估队列中携带CCR5 rs1799988 T等位基因者缓解率有低于C/C型的趋势(68% vs 81%,P=0.078)。
  • 按原发肿瘤部位分析,左-CCR5 C/C型、左-任何T、右-T/T、右-任何C型中位总生存分别为38.5、30.6、27.1、15.8个月(P<0.001),缓解率分别为91%、66%、92%、48%(P<0.001)。
  • 按原发肿瘤部位分析,CCL5左-A/A、左-任何G、右-A/A、右-任何G组中位总生存分别为38.3、21.7、21.9、18.3个月(P<0.001)。
  • 上述发现在对照队列中无统计学意义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epidermal growth factor receptor signalling blockade increases CCL5 expression that regulates either the anti-tumour immune response or tumour progression. We investigated the potential role of CCL5/CCR5 axis in cetuximab-based treatment in metastatic colorectal cancer (mCRC) patients. PATIENTS AND METHODS: Genomic DNA was extracted from 491 samples of two different cohorts with KRAS wild-type mCRC from the FIRE-3 trial: an evaluation cohort of 244 patients receiving cetuximab plus FOLFIRI and a control cohort of 247 patients receiving bevacizumab plus FOLFIRI. Single-nucleotide polymorphisms (SNPs) of CCL5 and CCR5 genes were analysed by polymerase chain reaction-based direct sequencing. RESULTS: Patients in the evaluation cohort with any CCL5 rs2280789G allele had shorter overall survival (OS) compared with those with the A/A variant (hazard ratio 1.56, P = 0.024). Patients carrying any CCR5 rs1799988T allele had a trend toward lower response rate than those with the C/C variant (68 vs. 81%, P = 0.078). In the analysis based on primary tumour location (left-sided [L]: right-sided [R]), remarkable differences in outcomes were observed between patients with L-CCR5 SNPs C/C variant (L-C/C), L-any T, R-T/T and R-any C as follows: median OS, 38.5, 30.6, 27.1 and 15.8 months, P < 0.001; response rate, 91, 66, 92 and 48%, P < 0.001. Median OS for CCL5 SNPs including L-A/A, L-any G, R-A/A and R-any G groups were 38.3, 21.7, 21.9 and 18.3 months, P < 0.001. The findings were not significant in the control cohort. CONCLUSION: Genetic variants of CCL5 and CCR5 SNPs may predict outcomes in mCRC patients receiving cetuximab-based treatment depending on tumour location.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Suenaga M, Stintzing S, Cao S, et al. Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. Eur J Cancer. 2018. PMID: 30554073. doi:10.1016/j.ejca.2018.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。